Phase II trial of weekly IV vinorelbine as a single agent in first-line advanced breast cancer chemotherapy: The Latin-American experience

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 18, Issue 5, 1995, Pages 392-396

  Bruno, S ^a   Puerto, V L ^a   Mickiewicz, E ^a   Hegg, R ^a   Texeira, L C ^a   Gaitan, L ^a   Martinez, L ^a   Fernandez, O ^a   Otero, J ^a   Kesselring, G ^a   Noguera, C ^a   Delgado, G ^a   Gaubert, P ^a   Delgado, F M ^a   Solidoro, A ^a  

^a Centre d'Immunologie Pierre Fabre   (France)

Author keywords

Adenocarcinoma of the breast; Navelbine; Single agent

Indexed keywords

NAVELBINE;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; BREAST ADENOCARCINOMA; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; METASTASIS; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL;

EID: 0029164670     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199510000-00006     Document Type: Article

References (0)